.After increasing $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on the general public market.The Eli Lilly-partnered biotech plan to provide on the Nasdaq under the sign “BIOA,” according to records filed along with the Securities and also Exchange Compensation. The business has actually certainly not publicly shared an anticipated financial quantity for the offering.The clinical-stage business boasts lead applicant azelaprag, a by mouth supplied tiny particle slated to enter into stage 2 testing in combo along with semaglutide– sold through Novo Nordisk under trademark name Wegovy for fat loss– in the initial fifty percent of following year. Semaglutide is likewise sold as Ozempic and also Rybelsus by Novo for diabetes.
Apelin receptor agonist azelaprag is actually created to blend properly with GLP-1 medications, enhancing fat burning while keeping muscular tissue mass. The investigational medication was actually discovered to be well-tolerated one of 265 people around eight period 1 tests, according to BioAge.Earlier, BioAge amassed the help of Lilly to manage a trial integrating azelaprag along with the Major Pharma’s GLP-1/ GIP receptor agonist tirzepatide, which is actually industried for diabetes mellitus as Mounjaro as well as Zepbound for weight-loss. The companions are presently performing a phase 2 trial of azelaprag and also tirzepatide, along with topline results anticipated in the third one-fourth of 2025.The biotech is actually also preparing a the hormone insulin level of sensitivity proof-of-concept trial analyzing azelaprag as a monotherapy in the first fifty percent of following year to assist prospective evidence development.
On top of that, the company prepares to talk to the FDA for authorization in the second half of 2025 to release human screening for an NLRP3 prevention targeting metabolic health conditions and also neuroinflammation.BioAge’s anticipated transfer to the public market adheres to a minor uptick in organized biotech IPOs coming from Bicara Therapeutics and Zenas Biopharma. Zooming out, the latest IPO landscape is a “blended image,” along with top notch companies still debuting on everyone markets, just in lowered amounts, according to PitchBook.